Genprex, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Genprex, Inc. (GNPX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-03-30
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-09-30 was $11.92, a 59500.00% increase year-over-year.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-09-30 was $0.02.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $0.00.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $11.92, a 1886.67% increase from fiscal 2022.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.60, a 40.59% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 | |||||
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | |||||
| 2023-12-31 | $11.92 10-K · filed 2025-04-01 | |||||
| 2023-09-30 | $11.92 10-Q · filed 2024-11-13 | $0.30 10-Q · filed 2023-11-14 | $0.30 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | $0.60 10-K · filed 2024-04-01 | $0.02 10-K · filed 2023-03-31 | ||||
| 2022-09-30 | $0.02 10-Q · filed 2023-11-14 | $0.02 10-Q · filed 2023-11-14 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 | |||||
| 2021-12-31 | $1.01 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | $1.01 10-Q · filed 2021-11-15 | |||||
| 2021-06-30 | $1.10 10-Q · filed 2021-08-13 | |||||
| 2021-03-31 | $1.69 10-Q · filed 2021-05-17 | |||||
| 2020-12-31 | $1.03 10-K · filed 2022-03-30 | |||||
| 2020-09-30 | $0.84 10-Q · filed 2020-11-12 | |||||
| 2020-06-30 | $0.30 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |